Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Indiana Botanic Gardens makes, markets, and sells herbal supplements, cosmetics, and other natural products.Its Botanic Choice and Botanic Spa lines feature such exotic ingredients as hoodia (an African desert plant), Indian Water Hyssop, and emu oil. In all, it sells about 1,700 items to customers throughout the US and abroad. The company does most of its business through its mail-order catalogue and online retail site; it also operates a retail store and offers wholesale sales for other retailers. Joseph E. Meyer, author of the classic reference book The Herbalist, founded Indiana Botanic Gardens in 1910. His great-grandson Tim Cleland is the company's president.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

Teikoku Pharma USA is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain and CNS. By applying our transdermal technologies to existing actives or co-developing new formulations, Teikoku helps pharmaceutical companies extend patent protections, diversify product lines, provide better delivery mechanisms, and promote brand loyalty. Teikoku charts new territory in prescription, OTC, and medical device markets around the world, transforming ideas into ideally delivered products that carry a competitive edge in quality and innovation.

Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania. Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. Lannett company's products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules. In addition, its products consist of pilocarpine HCl, primidone, probenecid, terbutaline sulfate, and unithroid tablets; oxycodone HCl oral solution; rifampin and ursodiol capsules; and phentermine HCl tablets and capsules. Lannett Company markets its products under the brand names of Diamox, Symmetrel, Lioresal, Urecholine, Fiorinal, Cleocin, Danocrine, Bentyl, Lanoxin, Persantine, Adoxa, Periostat, Estratest, Hydrodiuril, Dilaudid, Levoxyl/ Synthroid, Roxanol, PrimaCare ONE, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Actigall, and Fiorinal w/ Codeine #3. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.

Taro Pharmaceutical Industries manufactures drugs for cardiac, dermatological, neurological, and pediatric illnesses. It makes generic prescription and over-the-counter drugs at facilities in Canada, Ireland, Israel, the UK, and the US. It specializes in generics, but also produces private label and branded drugs. Its facilities are capable of producing topical, oral, and injectable formulations. The company also produces active pharmaceutical ingredients for use by its own facilities and sold to other drug makers. Taro Pharmaceutical routinely reinvests more than 10% of its sales into research into the development of new products. Its customers include large drugstore and grocery chains and discount retailers.

Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Hospira, Inc. company was founded in 2003 and is headquartered in Lake Forest, Illinois. Hospira, Inc., a specialty pharmaceutical and medication delivery company, engages in the development, manufacture, and marketing of pharmaceuticals and medication delivery systems in the United States and internationally. It offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems for hospitals, wholesalers, integrated delivery networks, and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company primarily provides specialty injectable pharmaceutical products that consist of generic injectable pharmaceuticals for analgesia, anesthesia, anti-infective, cardiovascular, and oncology therapeutic areas, as well as Precedex (dexmedetomidine HCl), a proprietary sedative. Its proprietary drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premixed formulations, and the ADD-Vantage System for preparing drug solutions from prepackaged drug powders or concentrates.Hospira, Inc. company also offers infusion therapy solutions and supplies that include I.V. solutions for general use; and I.V. nutrition products and solutions for the washing and cleansing of wounds or surgical sites. In addition, it provides medication management systems that include electronic drug delivery pumps, safety software, and administration sets that are used to deliver I.V. fluids and medications. Further, the company offers gravity administration sets, hemodynamic monitoring systems used to monitor cardiac function and blood flow in critically ill patients, disposable blood-pressure-sensing devices, blood sampling systems, catheter systems, and needle stick safety products. Additionally, Hospira involves in the provision of formulation development, and injectable and oral drug filling and finishing services.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.